Characteristics | Outcome | ||||
---|---|---|---|---|---|
Year | Study name | Population | Regimen | Drug | Efficacy (%, 95 CI) |
2010 | iPrEx [6] | MSM/TGW | Daily | TDF-FTC | 44% (15 to 63) |
2012 | Partners study [7] | Heterosexual HIV-discordant couples | Daily | TDF-FTC | 75% (55 to 87) |
TDF | 67% (44 to 81) | ||||
2012 | TDF2 [8] | Heterosexual | Daily | FTC- TDF | 62.2% (21.5 to 83.4) |
2012 | FEM-PrEP [13] | Heterosexual Females | Daily | TDF-FTC | 6% (−52 to 41%) |
2013 | Bangkok tenofovir study [31] | PWID | Daily | TDF | 48.9% (9.6 to 72.2) |
2014 | iPrEx extension [15] | MSM/TGW | Daily | TDF-FTC | 36% (−24 to 67)a |
2015 | VOICE [14] | Heterosexual Females | Daily | TDF-FTC | −4% (−49 to 27) |
TDF | −49% (− 129 to 3) | ||||
2015 | PROUD [9] | MSM | Daily | TDF-FTC | 86% (90% CI 64 to 96) |
2015 | IPERGAY [10] | MSM/TGW | Event-driven | TDF-FTC | 86% (40 to 98) |